How cancer could be cured by 2015

Cell Cycle

Volumn 4, Issue 2, 2005, Pages 268-277

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cancer; Chemotherapy; Leukemia; Selective agents; Tissue specific drugs

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CLADRIBINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLAVOPIRIDOL; FR 901228; GEFITINIB; GEMCITABINE; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PEMETREXED; RAPAMYCIN; TEMOZOLOMIDE; TOPOTECAN; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VALRUBICIN; VINCRISTINE; ZEBULARINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER THERAPY; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DNA SYNTHESIS; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; LEUKEMIA; LUNG CANCER; NEUROPATHY; ONCOGENE; PANCREAS ADENOCARCINOMA; PREDICTION; REVIEW; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

EID: 23644433384     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.2.1493     Document Type: Review

References (163)

1. von Eschenbach AC. NCI sets goal of eliminating suffering and death due to cancer by 2015. J Natl Med Assoc 2003 Jul; 95:637-9.
2. von Eschenbach AC. A vision for the national cancer program in the United States. Nat Rev Cancer 2004; 4:820-8.
3. Von Eschenbach AC. Introductory comments: Models of anti-cancer therapy. Cancer Biol Ther 2003; 2:S1.
4. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1:31-6.
5. Druker BJ. Imatinib: Paradigm or Anomaly? Cell Cycle 2004; 3:833-5.
6. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17:2998-3010.
7. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98:2483-7.
8. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95:881-7.
9. Logrono R, Jones DV, Faruqi S, Bhutani MS. Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). Cancer Biol Ther 2004; 3:251-8.
10. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
11. Arteaga CL. Inhibiting tyrosine kinases: Successes and limitations. Cancer Biol Ther 2003; 2:S79-83.
12. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-49.
13. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J Clin Oncol 2004; 22:2610-6.
14. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor-are we missing the mark? Lancet 2003; 362:62-4.
15. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: Toward novel use of kinase inhibitors (outlook). Cancer Biol Ther 2003; 2:137-40.
16. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4:956-65.
17. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in Lung cancer: Correlation with clinical response to Gefitinib Therapy. Science 2004; 304:1497-500.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell Lung cancer to Gefitinib. N Engl J Med 2004; 350:2129-39
19. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11.
20. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002; 29:63-4.
21. Baselga J, Arribas J. Treating cancer's kinase 'addiction'. Nat Med 2004; 10:786-7.
22. Blagosklonny MV. Do cells need CDK2 and Bcr-Abl? Cell Death Differ 2004; 11:249-51.
23. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
24. Settleman J. Inhibition of mutant EGF receptors by Gefitinib: Targeting an Achilles' Heel of Lung cancer. Cell Cycle 2004; 3:1496-7.
25. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148-58.
26. Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, Kornbluth S. Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol 2004; 24:10289-99.
27. McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene 2004; 23:7810-20.
28. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279:34227-39.
29. Giuriato S, Felsher DW. How cancers escape their oncogene habit. Cell Cycle 2003; 2:329-32.
30. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003; 101:2797-803.
31. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004; 6:577-86.
32. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300:949.
33. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5:25-35.
34. Huang Y, Lu M, Wu H. Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers? Cancer Cell 2004; 5:1-2.
35. Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 2001; 7:314-9.
36. Kaelin WGJ. Choosing anticancer drug targets in the postgenomic era. J Clin Invest 1999; 104:1503-6.
37. Sawyers CL. FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002; 1:413-5.
38. Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther 2003; 2:S55-63.
39. Rowinsky EK. Signal events: Cell signal transduction and its inhibition in cancer. Oncologist 2003; 8:S5-17.
40. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2:296-313.
41. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2003; 2:S16-22.
42. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? Cancer Cell 2004; 5:525-31.
43. Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-7.
44. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Houghten R, Pinilla C, Reed JC. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 2004; 279:48168-76.
45. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91:1-30.
46. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.
47. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304:1164-6.
48. Daley GQ. Gleevec resistance: Lessons for target-directed drug development. Cell Cycle 2003; 2:190-1.
49. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to Tyrosine kinase inhibition by mutant epidermal growth factor receptor Variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004; 10:3216-24.
50. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
51. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle 2004; 3:1537-42.
52. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 2004; 3:1035-42.
53. Imai J, Yashiroda H, Maruya M, Yahara I, Tanaka K. Proteasomes and molecular chaperones: Cellular machinery responsible for folding and destruction of unfolded proteins. Cell Cycle 2003; 2:585-90.
54. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 2004; 22:115-9.
55. Kwong YL, Todd D. Delicious poison: Arsenic trioxide for the treatment of leukemia. Blood 1997; 89:3487-8.
56. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2:705-13.
57. Fojo T, Bates S. Arsenic trioxide (As(2)O(3)): Still a mystery. Cell Cycle 2002; 1:183-186.
58. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-6.
59. Marks PA. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004; 3:534-5.
60. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10:2289-98.
61. Workman P. Overview: Translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003; 3:297-300.
62. Banerji U, Judson I, Workman P. The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr Cancer Drug Targets 2003; 3:385-90.
63. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3:377-83.
64. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537-43.
65. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2004; In press.
66. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2:222-32.
67. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4:335-48.
68. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7.
69. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-63.
70. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57:4029-35.
71. 2 arrest after DNA damage. Science 1998; 282:1497-501.
72. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev 1995; 14:3-5.
73. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432:316-23.
74. 2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3:305-13.
75. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6:151-8.
76. 2 DNA damage checkpoint. Mol Cancer Ther 2003; 2:543-8.
77. Carrassa L, Broggini M, Erba E, Damia G. Chk1 but not Chk2, is involved in the cellular response to DNA damaging agents: Differential activity in cells expressing or not p53. Cell Cycle 2004; 3:1177-81.
78. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2004; In press.
79. Tse AN, Schwartz GK. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 2004; 64:6635-44.
80. Zhou BB, Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25.
81. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics. Cell Cycle 2004; 3:419-21.
82. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: A preliminary report. J Urol 1985; 134:1127-30.
83. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985; 3:326-35.
84. Tolcher AW. Regulators of apoptosis as anticancer targets. Hematol Oncol Clin North Am 2002; 16:1255-67.
85. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998; 4:1393-403.
86. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
87. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nature Rev Cancer 2002; 2:221-5.
88. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104:1655-661.
89. Banerjee D, Bertino JR. Myeloprotection with drug-resistance genes. Lancet Oncol 2002; 3:154-58.
90. Workman P. Strategies for treating cancers caused by multiple genome abnormalities: From concepts to cures? Curr Opin Investig Drugs 2003; 4:1410-5.
91. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8:1104-7.
92. 2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002; 21:6249-54.
93. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001; 15:936-94.
94. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60:6259-65.
95. Kim K, Nakagawa H, Fei P, Rustgi AK, El-Deiry WS. Targeting Bcl-x(L) in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death Differ 2004; 11:583-7.
96. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279:40044-52.
97. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-8.
98. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-46.
99. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002; 1:103-10.
100. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49:6365-68.
101. Halicka HD, Seiter K, Feldman EJ, Traganos F, Mittelman A, Ahmed T, Darzynkiewicz Z. Cell cycle specificity of apoptosis during treatment of leukaemias. Apoptosis 1997; 2:25-39.
102. 1 Arrest. J Natl Cancer Inst 2000; 92:1999-2008.
103. Du L, Smolewski P, Bedner E, Traganos F, Darzynkiewicz Z. Selective protection of mitogenically stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. Int J Oncol 2001; 19:811-9.
104. 1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1:82-9.
105. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18:189-218.
106. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004; 3:372-9.
107. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 2004; 23:2934-49.
108. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-47.
109. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-62.
110. Kramer BW, Gotz R, Rapp UR. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 2004; 4:24.
111. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: Protection of normal cells and unshielding of cancer cells. Cell Cycle 2002; 1:375-82.
112. Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 2000; 60:3425-8.
113. MacKeigan JP, Collins TS, Ting JP-Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275:38953-6.
114. Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2003; 2:670-6.
115. Pardee AB, James LJ. Selective killing of transformed baby hamster kidney (BHK) cells. Proc Natl Acad Sci USA 1975; 72:4994-8.
116. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61:4301-5.
117. Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med 2003; 9:307-12.
118. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278:1064-8.
119. Grant S, Dent P. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors. Cell Cycle 2002; 1:383-8.
120. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer 2003; 3:821-31.
121. + T lymphocytes. Proc Natl Acad Sci USA 1999; 96:2982-7.
122. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
123. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89:1147-51.
124. de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: Evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 2004; 15:1825-33.
125. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28:251-65.
126. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2:389-96.
127. Rosenberg AG, von Eschenbach AC. Hormonal therapy for prostate cancer. Semin Surg Oncol 1990; 6:71-6.
128. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45.
129. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-39.
130. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21:383-91.
131. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 2000; 6:1248-52.
132. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95:990-1000.
133. Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE, Pieters R. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 2003; 102:4541-6.
134. Tissing WJ, Meijerink JP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003; 17:17-25.
135. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002; 20:215-29.
136. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004; 3:361-70.
137. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001; 2:300-6.
138. Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, Bazarbachi A. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003; 70:330-2.
139. Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. J Clin Oncol 1998; 16:3916.
140. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of nonHodgkin's lymphoma. Clin Cancer Res 2004; 10:2868-78.
141. + B-cell lymphoma: Long term follow-up of a phase I/II study. Blood 2004; In press
142. Vose JM. Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade nonHodgkin's lymphoma. Oncologist 2004; 9:160-72.
143. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:3430-5.
144. Li CJ, Li YZ, Pinto AV, Pardee AB. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA 1999; 96:13369-74.
145. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 2003; 100:2674-8.
146. Sutphin PD, Chan DA, Giaccia AJ. Dead cells don't form tumors: HIF-dependent cytotoxins. Cell Cycle 2004; 3:160-3.
147. Folkman J. Tumor angiogenesis: Therapeutic implications. N Eng J Med 1971; 285:1182-6.
148. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-7.
149. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.
150. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
151. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-7.
152. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
153. Rak J, Yu JL. Oncogenes and tumor angiogenesis: The question of vascular "supply" and vascular "demand". Semin Cancer Biol 2004; 14:93-104.
154. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36.
155. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004; 3:172-5.
156. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer 2003; 3:243-52.
157. Abbruzzese JL, Lippman SM. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 2004; 6:321-6.
158. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997; 278:1054-9.
159. Henson DE, Srivastava S, Kramer BS. Molecular and genetic targets in early detection. Curr Opin Oncol 1999; 11:419-25.
160. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359:403-4.
161. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJJ, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-20.
162. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3:267-75.
163. Lilleberg SL, Durocher J, Sanders C, Walters K, Culver K. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann NY Acad Sci 2004; 1022:250-6.